Use of SGLT2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease-A Multi-Country Report from the FOUNTAIN Platform

被引：0

作者：

Johannes, Catherine B. ^{[1
]}

Ziemiecki, Ryan ^{[1
]}

Pladevall-Vila, Manel ^{[1
]}

Kosvesdy, Csaba P. ^{[2
]}

Ebert, Natalie ^{[3
]}

Thomsen, Reimar W. W. ^{[4
,5
]}

Christiansen, Christian Fynbo ^{[4
,5
]}

Baak, Brenda ^{[6
]}

Robles Cabaninas, Celia ^{[7
]}

Kashihara, Naoki ^{[8
]}

Yano, Yuichiro ^{[9
]}

Kanegae, Hiroshi ^{[10
]}

Coleman, Craig I. ^{[11
]}

Okami, Suguru ^{[12
]}

Liu, Fangfang ^{[13
]}

Layton, J. Bradley ^{[1
]}

Vizcaya, David ^{[13
]}

Oberprieler, Nikolaus G. ^{[13
]}

机构：

[1] Res Triangle Inst Hlth Solut, Res Triangle Pk, NC USA

[2] Univ Tennessee, Hlth Sci Ctr, Knoxville, TN USA

[3] Charite Univ Med Berlin, Inst Publ Hlth, Berlin, Germany

[4] Aarhus Univ, Dept Clin Epidemiol, Aarhus, Denmark

[5] Aarhus Univ Hosp, Aarhus, Denmark

[6] PHARMO Inst Drug Outcomes Res, Utrecht, Netherlands

[7] FISABIO, Valencia, Spain

[8] Kawasaki Med Sch, Kurashiki, Okayama, Japan

[9] Juntendo Univ, Fac Med, Tokyo, Japan

[10] Genki Plaza Med Ctr Hlth Care, Tokyo, Japan

[11] Univ Connecticut, Storrs, CT USA

[12] Bayer Yakuhin Ltd, Osaka, Japan

[13] Bayer AG, Leverkusen, Germany

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

568

引用

页码：237 / 238

页数：2

共 50 条

[41] Renal Glucose Handling: Impact of Chronic Kidney Disease (CKD) and SGLT2 Inhibition In Patients With Type 2 Diabetes
Ferrannini, Ele
Veltkamp, Stephan A.
Van Dijk, Jan
Kadokura, Takeshi
Smulders, Ronald
DIABETES, 2012, 61 : A264 - A264
[42] SGLT2 Inhibitors to Slow Chronic Kidney Disease Progression: A Review
Maxson, Rebecca
Starr, Jessica
Sewell, Jeanna
Lyas, Claretha
CLINICAL THERAPEUTICS, 2024, 46 (01) : e23 - e28
[43] SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes
Singhal, Rohit
Hechanova, Lisa Aimee
CURRENT CARDIOLOGY REPORTS, 2022, 24 (03) : 183 - 189
[44] SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes
Rohit Singhal
Lisa Aimee Hechanova
Current Cardiology Reports, 2022, 24 : 183 - 189
[45] SGLT-2 inhibitors in patients with type 2 diabetes with acute kidney disease
Wu, Vin-Cent
Pan, Heng-Chih
Chen, Jui-Yi
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I205 - I206
[46] SGLT-2 inhibitors in patients with type 2 diabetes with acute kidney disease
Wu, Vin-Cent
Pan, Heng-Chih
Chen, Jui-Yi
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
[47] Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?
Qiu, Mei
Ding, Liang-Liang
Zhan, Ze-Lin
Zhou, Hai-Rong
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2021, 87 : 98 - 99
[48] SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond
Tuttle, Katherine R.
LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (01): : 3 - 5
[49] Combined use of SRAA blockers and SGLT2 inhibitors for reduction of proteinuria in paediatric patients with chronic kidney disease
Lopez-Baez, Victor
Lopez Espinoza, Yarima
Calzada Banos, Yolanda
Aguilar, Ana
Fortes, Emma
Jimenez Moreno, Marta
Arango Sancho, Pedro
Madrid Aris, Alvaro
PEDIATRIC NEPHROLOGY, 2024, 39 (01) : S64 - S64
[50] Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
Zhao, Li-Min
Zhan, Ze-Lin
Ning, Jie
Qiu, Mei
FRONTIERS IN PHARMACOLOGY, 2022, 12

← 1 2 3 4 5 →